Navigation Links
Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer
Date:3/13/2008

SOUTH SAN FRANCISCO, Calif., March 13 /PRNewswire/ -- Raven biotechnologies, inc., a privately held company focused on the discovery and development of monoclonal antibody therapeutics (MAbs) for cancer, today announced that it has initiated a Phase 2 study of RAV12, its lead clinical product, in combination with gemcitabine in the treatment of patients with metastatic pancreatic cancer.

The Phase 2 Pancreatic Cancer Study will be conducted at approximately 20 institutions in the US. The first institution to open the trial is the Fox Chase Cancer Center in Philadelphia, PA. Eight sites will participate through the clinical trials consortium, the Pancreatic Cancer Research Team. More information regarding the study can be found at http://www.clinicaltrials.gov.

After an initial dose-escalation run-in segment of approximately 18 patients, the Phase 2 trial will enroll 63 patients in an efficacy segment. The target dose and schedule of RAV12, 0.75 mg/kg twice weekly, was chosen in a recently completed Phase 1/2a trial that involved 53 patients. Final analysis of the Phase 1/2a study will be available the third quarter of 2008.

About RAV12

RAV12 is a novel, chimeric monoclonal antibody that is directed against a primate-specific glycotope (sugar structure) that is widely displayed on the surfaces of tumor cells, particularly those of gastrointestinal origin (gastroesophageal, pancreatic, and colorectal cancers). Preclinical studies have demonstrated that RAV12 may kill tumor cells in a number of ways: first, the antibody is directly cytotoxic to a human colon cancer cell line in vitro through induction of oncotic cell death, a form of cell death characterized by cell and organelle swelling and loss of membrane integrity; second, the antibody mediates antibody-dependent cellular cytotoxicity; third, the antibody mediates complement dependent cell killing; and finally, the antibod
'/>"/>

SOURCE Raven biotechnologies, inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
2. Raven Announces Continued Enrollment of Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
3. Raven Announces Phase 1 Clinical Trial Results of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
4. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
5. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
6. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
7. Inclinix Announces New Patent for Expert System Platform
8. Genzyme Announces Presentation of New Positive Data on Carticel(R)
9. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
10. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
11. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... CITY, Kan. , Nov. 28, 2014 ... therapeutics company focused on the licensing or acquisition, development ... and other companion animals, today announced that it will ... Healthcare Conference, to be held December 2-3, 2014, at ... York . Steven St. Peter ...
(Date:11/28/2014)... 30 September 201430 September 2013Turnover 546,011 , 534,641 , ... , 339,113 , 13.3 Hospital Management Service ... 49.5 Medical Insurance Administration Service Income , 2,394 ... Sales , 94,580 , 142,683 , ... 9,219 , (68.4) Impairment Loss on Fixed Assets ...
(Date:11/26/2014)... 2014  Thoratec Corporation (NASDAQ: THOR ), ... to save, support and restore failing hearts, said today ... On Tuesday, December 2, the company will ... Healthcare Conference.  D. Keith Grossman , President and ... company beginning at 11:30 a.m., Eastern Standard Time (8:30 ...
Breaking Medicine Technology:Aratana Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference 2Golden Meditech Announces 2014 / 2015 Interim Results 2Golden Meditech Announces 2014 / 2015 Interim Results 3Golden Meditech Announces 2014 / 2015 Interim Results 4Golden Meditech Announces 2014 / 2015 Interim Results 5Golden Meditech Announces 2014 / 2015 Interim Results 6Golden Meditech Announces 2014 / 2015 Interim Results 7Golden Meditech Announces 2014 / 2015 Interim Results 8Thoratec Announces Presentations At Investor Conferences For December 2014 2
... Mass., Oct. 11, 2011 Merrimack Pharmaceuticals, Inc. ... dosed in a randomized Phase 2 clinical trial ... targets ErbB3, combined with paclitaxel (Taxol®) in the ... (Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO) The Phase 2 ...
... BEIJING, Oct. 11, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, ... leading China-based advanced in-vitro diagnostic ("IVD") company, today announced ... Kingdom Intellectual Property Office (the "UKIPO") and Notice of ... Patent and Trademark Office (the "USPTO"). All patents relate ...
Cached Medicine Technology:Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients 2China Medical Technologies Receives Two Patents Granted by the UKIPO and Notice of Allowance for Four Patent Applications from the USPTO 2China Medical Technologies Receives Two Patents Granted by the UKIPO and Notice of Allowance for Four Patent Applications from the USPTO 3
(Date:11/28/2014)... THURSDAY, Nov. 27, 2014 (HealthDay News) -- Celebration ... are misused on Thanksgiving Day, experts say. Over ... hot-oil burns have occurred while people were using turkey ... "I have actually cared for a patient who ... should not be done in any circumstances," Dr. Arthur ...
(Date:11/28/2014)... November 28, 2014 PreDiabetes ... and treatment, helped employees learn their risk for ... blood screening at a local school in partnership ... Work initiative. , As the Presenting Sponsor ... , PreDiabetes Centers is co-hosting diabetes-prevention presentations at ...
(Date:11/28/2014)... New York, New York (PRWEB) November 28, 2014 ... lawsuits ( http://www.consumerinjurylawyers.com/stryker-rejuvenate/stryker-hip-lawsuits/ ) have now been filed ... pair of recalled metal implants, Bernstein Liebhard LLP ... November 18th in Bergen County Superior Court reflects ... and ABG II modular-neck hip stems, which were ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 Patten Pecans, ... locally grown. With those passions driving them, they've added ... Grown. Having tried other pecans oils, they've found this ... Georgia to be exceptionally flavorful, retaining the buttery pecan ... same nutritional benefits found in pecans nuts ...
(Date:11/28/2014)... Before that Thanksgiving meal even had time to digest, ... season. Today, people will stand in line for hours to ... shopping day of the year. , But instead of ... dentist Dr. Ronald Receveur is asking the public to ... brighten a few smiles. , The gifts he suggests are:, ...
Breaking Medicine News(10 mins):Health News:Turkey Fryer Mishaps Can Cause Serious Burns 2Health News:PreDiabetes Centers Offers Workplace Diabetes Screening at Local School 2Health News:More than 2,100 Stryker Hip Lawsuits Included in New Jersey Litigation after Settlement Announcement, Bernstein Liebhard LLP Reports 2Health News:More than 2,100 Stryker Hip Lawsuits Included in New Jersey Litigation after Settlement Announcement, Bernstein Liebhard LLP Reports 3Health News:Patten Pecans Goes Local with Nutritious Georgia Pecan Oil 2Health News:New Albany Dentist Offers Gift Ideas That Can Improve Oral Health 2Health News:New Albany Dentist Offers Gift Ideas That Can Improve Oral Health 3Health News:New Albany Dentist Offers Gift Ideas That Can Improve Oral Health 4
... type of skin cancer. In this paper, Leif Ellisen and ... and p73 in SCC cells, and discovered a feedback loop ... SCC, they found that inhibiting one of these miRs decreased ... highlighting a new potential therapeutic target. , Squamous cell carcinoma ...
... Reinberg HealthDay Reporter , SUNDAY, Jan. 9 ... (best known by the brand name of Prozac) appear ... sufferers, French researchers have found. Not surprisingly, patients ... depression after their stroke, the study found. Paralysis ...
... The search for a universal flu vaccine has received a ... strain. Several patients infected with the 2009 H1N1 strain ... strains, scientists from Emory University School of Medicine and the ... Monday in the Journal of Experimental Medicine . ...
... Hope for new ways of treating devastating neurodegenerative disorders ... trans-Atlantic team of researchers thanks to the use of ... Leicester, scientists from the University of Lisbon (led by ... Francisco (led by Dr Paul Muchowski) collaborated to generate ...
... areas of the United States are more likely to ... areas, particularly when comparing non-whites living in different parts ... new study published early online in Cancer , ... research is needed to better understand how colorectal cancer ...
... (HealthDay News) -- The first study to focus solely on ... the Sept. 11, 2001 attacks on the World Trade Center ... fact, of the 3,271 evacuees of the Twin Towers surveyed ... from at least one current post-traumatic stress symptom, while 15 ...
Cached Medicine News:Health News:Prozac May Speed Physical Rehabilitation After Stroke 2Health News:Prozac May Speed Physical Rehabilitation After Stroke 3Health News:Pandemic flu strain could point way to universal vaccine 2Health News:Pandemic flu strain could point way to universal vaccine 3Health News:New hope in fight against Huntington's disease 2Health News:Race affects regional colorectal cancer screening disparities 2Health News:Many Survivors of World Trade Center Attacks Suffered PTSD: Study 2
... Cobas Integra 400 plus, innovation means ... of reaction cuvettes and im-proved operator ... menu and ease-of-use required for true ... only possible with only one analytical ...
... The Advia 1650 has ... (as low as 2 L/test), ... 80 L/test) and water consumption ... management efficiency. Optional universal rack ...
Iron UIBC (UIBC Buffer + Color + Std.). An Automated analyzer test kits....
HDL Cholesterol, liquid....
Medicine Products: